Method
Patients included in the study had a documented T3 ± T4 M0 ± M1 prostate cancer, WHO 0 ± 1, age`85, previously untreated. They were randomised at inclusion either to IAS or CAS. Patients randomised to IAS were treated with maximal androgen blockade six months every year (on and off semesters). Biochemical relapse was declared following an`on semester' when PSA level exceeded twice the level of PSA obtained after the ®rst six months of androgen suppression. Follow-up was based on a biannual consultation including PSA and testosterone measures and a quality of life questionnaire (EORTC QLQ-C30).
Results
The study started at the beginning of 1997 and the inclusion phase ended in January 2000 (120 patients randomised). First analysis of biochemical relapse rate and quality of life are planned for December 2001.
Conclusion
The small clinical studies conducted to date show the feasibility of IAS. However, the results of randomised trials currently underway are needed to determine the effect of IAS on survival and quality of life. The best treatment algorithm is yet to be determined. Testosterone recovery is likely to be an important factor to consider.
